By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dimerix Bioscience said today that it will help Takeda Cambridge Limited study G-protein coupled receptors (GPCR) that Takeda believes may be developed into drug compounds.

Under the agreement, Australia-based Dimerix will use its GPCR-HIT platform to form complexes called heteromers that can be used to screen for and profile compounds for Takeda Cambridge, which is a UK-based subsidiary of Japan's Takeda Pharmaceutical.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.